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Protease-activated receptor 1 (PAR1), a G protein-coupled receptor for the coagulant protease thrombin, is
irreversibly activated by proteolysis. Unactivated PAR1 cycles constitutively between the plasma membrane
and intracellular stores, thereby providing a protected receptor pool that replenishes the cell surface after
thrombin exposure and leads to rapid resensitization to thrombin signaling independent of de novo receptor
synthesis. Here, we show that AP2, a clathrin adaptor, binds directly to a tyrosine-based motif in the
cytoplasmic tail of PAR1 and is essential for constitutive receptor internalization and cellular recovery of
thrombin signaling. Expression of a PAR1 tyrosine mutant or depletion of AP2 by RNA interference leads to
significant inhibition of PAR1 constitutive internalization, loss of intracellular uncleaved PAR1, and failure of
endothelial cells and other cell types to regain thrombin responsiveness. Our findings establish a novel role for
AP2 in direct regulation of PAR1 trafficking, a process critically important to the temporal and spatial aspects
of thrombin signaling.
G protein-coupled receptors (GPCRs) comprise the largest
family of receptors in the mammalian genome and elicit cel-
lular responses to diverse extracellular stimuli (30). Intracellu-
lar trafficking of GPCRs controls temporal and spatial aspects
of receptor signaling, including signal termination via removal
of activated receptors from G-proteins and signaling effectors
at the plasma membrane. Recent studies indicate that activated
GPCRs can also signal internally at endocytic vesicles (1, 34).
Once agonist dissociates from internalized receptor, GPCRs are
then recycled back to the cell surface in a resensitized state com-
petent to signal again. Trafficking of internalized GPCRs from
endosomes to lysosomes with the consequent receptor degrada-
tion is also an important process that terminates receptor signal-
ing (36, 37). The regulation of GPCR internalization, recycling,
and lysosomal sorting involves specific interactions between re-
ceptor “sorting” motifs and endocytic adaptor proteins. However,
the mechanisms that mediate trafficking of GPCRs through the
endocytic pathway remain poorly defined.
Protease-activated receptor 1 (PAR1), prototype of a family
of proteolytically activated GPCRs, is a receptor for the coagu-
lant protease thrombin. PAR1 is the predominant mediator of
thrombin signaling in human platelets, endothelial cells, fibro-
blasts, and smooth muscle cells and elicits a variety of cellular
responses critical for normal vascular responses as well as
cardiovascular disease processes (6, 21). PAR1 is activated
by an unusual, irreversible proteolytic mechanism. Thrombin
cleaves the extracellular amino terminus of the receptor, un-
masking a new amino terminus that acts as a tethered ligand by
binding intramolecularly to the receptor to trigger signaling (5, 38,
39). Synthetic peptides that mimic this newly formed amino-
terminus can activate PAR1 independent of thrombin and
receptor cleavage. The irreversible nature of proteolytic PAR1
activation, by generating a tethered ligand that cannot diffuse
away, is distinct from the reversible activation of most GPCRs,
raising the question, How do cells regulate thrombin signaling?
PAR1 trafficking is essential for the fidelity of thrombin
signaling. In unstimulated fibroblasts and endothelial cells,
PAR1 cycles constitutively between the cell surface and an
intracellular compartment, forming a cytosolic receptor pool
protected from thrombin cleavage and activation (13, 15, 18).
Upon thrombin exposure, cell surface PAR1 is cleaved, acti-
vated and then internalized, sorted predominantly to lyso-
somes, and degraded (16, 36). Internalization and lysosomal
sorting of irreversibly activated PAR1 are both critical for
signal termination (36, 37). After thrombin is removed, un-
cleaved PAR1 moves from the intracellular protected pool to
the cell surface. This replenishment of the cell surface with
uncleaved PAR1 allows for rapid recovery of thrombin signal-
ing independent of de novo receptor synthesis (13). However,
the sorting motifs and endocytic adaptor proteins that specify
the distinct trafficking behaviors of PAR1 are not known.
Arrestins are multifunctional adaptor proteins known to in-
teract with the clathrin endocytic machinery to mediate GPCR
internalization. We previously found that PAR1 internaliza-
tion, although dependent on clathrin and dynamin, occurs in-
dependent of arrestins (4, 25, 35). Given this observation, and
the presence of tyrosine-based motifs in the cytoplasmic tail of
PAR1, we examined the function of the adaptor protein com-
plex 2 (AP2). AP2 is a plasma membrane-localized clathrin
adaptor composed of , 2, 2, and 2 adaptin subunits (3).
The 2 subunit binds directly to tyrosine-based sorting signals
within the cytoplasmic regions of transmembrane proteins to fa-
cilitate internalization through clathrin-coated pits. Our studies
here reveal that AP2 directly regulates PAR1 constitutive inter-
nalization and is essential for resensitization of endothelial cells
and other cell types to thrombin signaling.
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Reagents and antibodies. Human -thrombin was obtained from Enzyme
Research Laboratories. The PAR1 agonist peptides SFLLRN and TFLLRN
PNDK were synthesized as the carboxyl amide and purified by high-pressure
liquid chromatography by the University of North Carolina Peptide Facility.
N-terminal biotinylated peptides corresponding to the carboxy terminus of hu-
man PAR1 (amino acids 396 to 425) were synthesized and purified by high-
pressure liquid chromatography by the Tufts University Core Facility (Boston,
MA). Hirudin, cycloheximide, carbachol, isoproterenol, uridine triphosphate
(UTP), and sucrose were purchased from Sigma. Calcium indicator dye Fura2-
acetoxymethyl-ester (Fura2-AM), pluronic acid, 4-bromo A-23187 ionophore,
transferrin-Alexa-488, and Alexa-488- and Alexa-594-conjugated goat anti-
mouse antibodies were obtained from Molecular Probes. Monoclonal M1 anti-
FLAG, -adaptin, -actin, and glutathione S-transferase (GST) antibodies were
obtained from Sigma. Anti-AP50 (2), anti--adaptin, and anti-early endosome
antigen (EEA1) monoclonal antibodies were from BD Biosciences. Polyclonal anti-
His6 antibody was obtained from Abcam Inc. Anti--arrestin polyclonal antibody
A1CT was generously provided by R. J. Lefkowitz (Duke University). A rabbit
polyclonal anti-PAR1 antibody was generated against the amino-terminal peptide
sequence YEPFWEDEEKNESGLTEYC, as previously described (17). Horse-
radish peroxidase-conjugated goat anti-mouse and anti-rabbit secondary anti-
bodies were from Bio-Rad.
cDNAs and cell lines. A previously published cDNA encoding wild-type PAR1
containing an amino-terminal FLAG epitope was used to generate receptor
mutants (18). Mutations were introduced using QuickChange site-directed mu-
tagenesis (Stratagene) and confirmed by dideoxy sequencing. FLAG-tagged
2-adrenergic receptor cDNA was a gift from M. von Zastrow (University of
California, San Francisco). A plasmid encoding green fluorescent protein (GFP)-
tagged, dominant-negative (K44A) dynamin 2 was generously provided by M.
McNiven (Mayo Clinic and Foundation). HeLa cells stably expressing FLAG-
tagged PAR1 wild-type and mutants were generated and maintained as previ-
ously described (35). Human umbilical vein endothelial cells (HUVECs) were
obtained from Clonetics and maintained according the manufacturer’s instruc-
tions. HUVECs at early passages were used for all experiments.
siRNAs. HeLa cells were transiently transfected with 50 nM of nonspecific
(NS) or 2-specific small interfering RNAs (siRNAs) using Lipofectamine 2000
according to the manufacturer’s instructions. Experiments were performed 60 h
after transfections. HUVECs (1  106) were electroporated with a 600 nM
concentration of either NS or 2 siRNA using technology developed by Amaxa,
Inc., and experiments were carried out 48 h later. The 2 siRNA targeting the
mRNA sequence 5-GTG GAT GCC TTT CGG GTC A-3 was previously
described (20) and synthesized by Dharmacon, Inc. The NS siRNA 5-CTA CGT
CCA GGA GCG CAC C -3 was used as a negative control.
Internalization assays. Constitutive and agonist-induced PAR1 internaliza-
tion were assessed using our previously published receptor-antibody uptake
assay (26, 35).
Immunofluorescence confocal microscopy. HeLa cells or HUVECs were pre-
incubated with rabbit polyclonal anti-PAR1 antibody for 1 h at 4°C to label the
surface cohort, washed, and then left untreated or treated in the absence or
presence of agonist for various times at 37°C. Cells were fixed and processed for
confocal microscopy as we previously described (25, 40). Colocalization of 2-
adaptin was assessed by incubating permeabilized cells with anti--adaptin antibody
for 1 h at 25°C, followed by species-specific fluorophore-conjugated secondary
antibodies, and then imaged by confocal microscopy. Colocalization of PAR1
with -adaptin was examined in fixed cells permeabilized with 0.2% Triton X-100
diluted in phosphate-buffered saline (PBS), after incubation with species-specific
fluorophore-conjugated secondary antibodies using confocal microscopy. The
extent of colocalization of PAR1 with either 2-adaptin or -adaptin was quan-
titated by counting the number of PAR1-positive puncta that costained with
2-adaptin or -adaptin, indicated by the yellow area in the merged image as
previously described (40). The data are expressed as the percentage of PAR1-
positive puncta that costained with either 2-adaptin or -adaptin and represent
the averages of many cell samples examined in independent experiments. To
assess PAR1 colocalization with EEA1, permeabilized cells were incubated with
anti-EEA1 antibody for 1 h at 25°C, washed, and then incubated with species-
specific secondary fluorophore-conjugated antibodies and imaged by confocal
microscopy. Transferrin uptake was assessed in serum-deprived HeLa cells by
incubation with Alexa-488-conjugated transferrin for 1 h at 4°C; cells were
washed and then warmed to 37°C for 10 min and internalized transferrin–Alexa-
488 was imaged by confocal microscopy. Images were collected using a Fluoview
300 laser scanning confocal imaging system (Olympus) configured with an IX70
fluorescent microscope fitted with a PlanApo 60 oil objective. Fluorescent
images, X-Y sections at 0.28 m, were collected sequentially at 800  600
resolution with 2 optical zoom. The final composite image was created using
Adobe Photoshop CS.
Immunoblotting. To detect 2 expression, total cell lysates were resolved by
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis, transferred to
membranes, and immunoblotted with a monoclonal anti-AP50 (2) antibody.
Blots were then stripped and reprobed with a monoclonal antiactin antibody.
Immunoblots were developed with ECL-PLUS (Amersham) and imaged by
autoradiography.
GST pull-down and surface plasmon resonance (SPR) binding assays. To
generate GST fused to the PAR1 cytoplasmic (C)-tail domain, an EcoR I and
BamH I insert containing a glycine/serine spacer (GSSG) and PAR1 C-tail
residues 374 to 425 was ligated into compatible sites of pGEX2TK (Amersham).
GST constructs were transformed into BL21(DE3) Escherichia coli, and fusion
proteins were induced and purified using standard techniques previously de-
scribed (41). A His6-tagged 2 expression plasmid (24), encompassing the carboxyl
terminal amino acid residues 160 to 435 (provided by D. J. Owen, University of
Cambridge, United Kingdom), was transformed into BL21(DE3)pLys-S E. coli. Six
liters of culture was grown at 37°C to an optical density at 600 nm (OD600) of 0.8
with progressive temperature reduction to 18°C prior to induction of His6-2
expression with 50 M IPTG (isopropyl--D-thiogalactopyranoside) for 20 h at
18°C. The soluble cell lysate fraction was subjected to Ni2-nitrilotriacetic acid
(Ni-NTA) resin affinity chromatography, followed by size exclusion chromatog-
raphy using established methods (41). Monodispersed fractions of His6-2 pro-
tein were pooled and concentrated using a YM-10 centrifugal filter (Millipore)
in a final buffer containing 20 mM HEPES, pH 7.5, 200 mM NaCl, 2 mM
dithiothreitol, and 10% glycerol.
For GST pull-down binding assays, 20 g of GST-PAR1 C-tail fusion protein
or GST alone was immobilized on glutathione-Sepharose 4B beads and then
incubated with 20 g of His-tagged 2 protein for 3 h at 4°C in binding buffer (10
mM Tris-HCl, pH 7.4, 5 mM EDTA, 0.2% Triton X-100). Binding reactions were
then washed three times with binding buffer (without Triton X-100). Proteins
that remained bound were eluted in 2 SDS gel loading buffer (100 mM Tris-
HCl, pH 6.8, 10% SDS, 0.2% bromophenol blue, 1 mM dithiothreitol, and 20%
glycerol), resolved by SDS-polyacrylamide gel electrophoresis, transferred to
membranes, and immunoblotted with anti-His antibody or anti-GST antibody.
Immunoblots were developed with ECL or ECL-PLUS (Amersham) and imaged
by autoradiography.
SPR binding assays were performed at 25°C using a BIAcore 3000 in the
University of North Carolina Pharmacology Protein Core. N-terminally biotin-
ylated PAR1 C-tail peptides (diluted to 1 g/ml in BIA running buffer [10 mM
HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% NP-40]) were bound to
separate flow cells of a streptavidin-coated biosensor chip (SA5; Biacore) to a
surface density of 1,000 resonance units. Prior to injection, His6-2 protein was
diluted to desired concentrations in BIA running buffer. A total of 50 l of
His6-2 protein was then simultaneously injected over flow cells at 10 l/min,
followed by a 200-s dissociation in BIA running buffer. All sensorgram curves
were corrected for bulk buffer refractive index shifts and nonspecific binding by
subtracting corresponding traces from a negative control blank surface. Following
each injection, surfaces were regenerated with a 10-l injection of 500 mM NaCl
plus 20 mM NaOH at 20 l/min. Binding curves and affinity calculations were
conducted using BIAevaluation (version 3.0) and GraphPad Prism (version 4.0b).
Intracellular calcium measurements. Cells were grown on glass coverslips to
a cell density of approximately 30 to 40% of confluence. Intracellular calcium was
measured and quantified essentially as previously described (27). Cells loaded
with 5 M Fura2 were placed in a flowthrough chamber and superfused contin-
uously with Hanks balanced salt solution in the presence or absence of agonists.
Cells were exposed to alternating excitation wavelengths of 340 and 380 nm, and
fluorescence emission at 510 nm was monitored using an integrating charge-
coupled-device camera. The 340/380-nm fluorescence emission ratio was deter-
mined, and intracellular Ca2 concentration was determined using the equation
of Gyrnkiewicz et al. (12). The data were recorded and processed using InCyt
IM2 digital imaging system (Intracellular Imaging Inc.).
Data analysis. Data were analyzed using Prism 4.0 software, and statistical
significance was determined using InStat 3.0 (GraphPAD). Group comparisons
were made using an unpaired Student’s t test.
RESULTS
PAR1 interacts directly with 2 in vitro and colocalizes with
endogenous AP2 in vivo. Using arrestin-deficient mouse em-
bryonic fibroblasts, we previously found that PAR1 internalizes
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through a clathrin- and dynamin-dependent pathway indepen-
dent of arrestin function (25). Arrestin-independent PAR1
internalization through clathrin-coated pits is also observed in
HeLa cells and other cell types (4, 35) (see Fig. S1 in the
supplemental material). To delineate the mechanism respon-
sible for PAR1 internalization through clathrin-coated pits, we
initially examined whether PAR1 could interact with the 2
subunit of AP2. Purified, His6-tagged 2 protein was found to
bind directly to a GST-PAR1 C-tail fusion protein absorbed to
glutathione-Sepharose beads, but not to GST protein alone
(Fig. 1A). We next determined whether PAR1 colocalizes with
the clathrin adaptor AP2 in intact cells using confocal micros-
copy. HeLa cells stably expressing FLAG-tagged PAR1 were
incubated with a polyclonal anti-PAR1 antibody at 4°C to
ensure that only cell surface receptors would be labeled. Cells
were then warmed to 37°C for 2.5 min in the absence of
agonist; under these conditions unactivated PAR1 is recruited
to clathrin-coated pits (35). Cells were then fixed and immu-
nostained for PAR1 and the AP2 subunit 2-adaptin. Approx-
imately 30% of PAR1-positive puncta costained for 2-adaptin
(Fig. 1B), suggesting that the majority of constitutively inter-
nalized receptors recruited to clathrin-coated pits colocalize
with AP2 in intact cells (Fig. 1B).
AP2 is essential for PAR1 constitutive internalization. To
assess AP2 function in PAR1 trafficking, we used siRNA tar-
geting the 2 subunit to deplete HeLa cells of endogenous
AP2 complex (20). Expression of 2 was virtually abolished in
cells transiently transfected with 2 siRNA compared to cells
transfected with a nonspecific control (Fig. 2A, inset). Cells
transfected with 2 siRNA also showed significant decreases in
2-adaptin expression (Fig. 2C), consistent with a loss of en-
dogenous AP2 complex (20). Inhibition of transferrin uptake
in 2 siRNA-transfected cells (see Fig. S2 in the supplemental
material) further indicates that 2 knockdown is sufficient to
deplete HeLa cells of AP2 function, as the transferrin receptor
is known to internalize constitutively and recycle through an
AP2-, clathrin- and dynamin-dependent pathway (3).
To determine whether AP2 is necessary for PAR1 internal-
ization, a stable HeLa cell line expressing FLAG-tagged PAR1
was labeled with anti-FLAG antibody and then incubated with
or without agonist at 37°C for various times to allow internal-
ization of receptor-bound antibody. In control siRNA-trans-
fected cells not exposed to agonist, 20% of antibody initially
bound to the cell surface was internalized at steady state (Fig.
2A and B), consistent with the extent of PAR1 constitutive
internalization observed in other cell types (13, 32). In con-
trast, PAR1 constitutive internalization was inhibited signifi-
cantly in 2 siRNA-transfected cells (Fig. 2A and B), in spite
of an increase in steady-state amounts of surface receptor in
these cells (data not shown). These findings suggest that AP2
is necessary for PAR1 constitutive internalization. Exposure to
the agonist peptide SFLLRN for 10 min caused substantial
PAR1 internalization irrespective of siRNA treatment (Fig.
2B). Interestingly, in cells depleted of 2, activated PAR1
internalization occurred through a clathrin- and dynamin-de-
pendent pathway (see Fig. S3 in the supplemental material).
These findings suggest that agonist-activated PAR1 internal-
ization is independent of AP2 function.
Immunofluorescence studies of PAR1-expressing HeLa cells
were consistent with an AP2-dependent regulation of receptor
constitutive internalization. In control siRNA-transfected cells,
a 10-min incubation at 37°C caused PAR1 to redistribute from
the cell surface into endocytic vesicles (Fig. 2D), consistent
with tonic cycling between the plasma membrane and an
intracellular compartment. In contrast, cell surface PAR1
failed to internalize in unstimulated 2 siRNA-transfected
cells after 10 min at 37°C (Fig. 2D). Similar results were ob-
served in cells transfected with a different 2 siRNA targeting
a distinct mRNA sequence (9) (data not shown). The addition
of SFLLRN, however, induced significant accumulation of
internalized PAR1 in both control- and 2 siRNA-transfected
cells (Fig. 2D), confirming that AP2 is not required for agonist-
activated PAR1 internalization.
To determine whether AP2 regulates trafficking of endoge-
nous receptor in native cells, we examined PAR1 internaliza-
FIG. 1. The 2 subunit of AP2 interacts with the PAR1 C tail in
vitro and PAR1 colocalizes with endogenous AP2 in intact cells.
(A) GST-PAR1 C-tail fusion protein or GST protein alone absorbed
to glutathione-Sepharose beads was incubated with purified His-
tagged 2. Bound proteins were eluted and immunoblotted with an
anti-His antibody (upper panel). An aliquot of purified His-tagged 2
representing 10% input is shown in the last lane. Membranes were
stripped and reprobed with an anti-GST antibody to determine the
total amount of GST-PAR1 C tail and GST protein loaded in various
lanes (lower panel). (B) HeLa cells stably expressing FLAG-tagged
PAR1 were preincubated with anti-PAR1 antibody for 1 h at 4°C such
that only cell surface receptor-bound antibody. Cells were then incu-
bated for 2.5 min at 37°C with no agonist, fixed, permeabilized, and
immunostained for PAR1 (red) using a polyclonal anti-PAR1 antibody
and for endogenous 2-adaptin (green) using a monoclonal anti-2-
adaptin antibody and imaged by confocal microscopy. Colocalization
of PAR1 with AP2 is shown in yellow in the merged image. The image
shown is representative of many cells examined in three independent
experiments. Scale bar, 2 m.
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tion in HUVECs. HUVECs electroporated with 2 siRNA
showed significant loss of 2 protein and 2-adaptin expres-
sion compared to control siRNA-treated cells, suggesting that
in these cells endogenous AP2 complex has been depleted
(Fig. 3). A significant amount of internalized PAR1 was found
in endocytic vesicles in control cells after 15 min at 37°C (Fig.
3B). By contrast, PAR1 failed to redistribute to endocytic
vesicles in 2 siRNA-transfected cells (Fig. 3B), suggesting an
AP2-dependent regulation of PAR1 constitutive internaliza-
tion in HUVECs. Incubation with the PAR1-specific agonist
peptide TFLLRNPNDK caused a marked increase in recep-
tor-containing endocytic vesicles in both control- and 2
siRNA-transfected cells (Fig. 3C), indicating that activated
PAR1 internalizes independent of AP2. Together these find-
ings reveal a novel function for AP2 in regulating PAR1 con-
stitutive internalization.
A distal tyrosine-based motif within PAR1 is required for 2
binding and constitutive internalization. The 2 subunit of
AP2 binds directly to tyrosine-based sequences in cytoplasmic
domains of transmembrane proteins and thereby facilitates
recruitment to clathrin-coated pits at the cell surface (3). A
search of the PAR1 sequence for such sorting signals revealed
two highly conserved sequences in the C-tail region conform-
ing to the YXXØ motif (where Y denotes tyrosine, X is any
amino acid, and Ø is a bulky hydrophobic amino acid) (Fig.
4A). The interaction of 2 with tyrosine-based sequences is
strictly dependent on the tyrosine and bulky hydrophobic res-
idue positions; however, residues flanking the motif also con-
tribute to 2 binding (3). To test the role of each tyrosine-
based motif in PAR1 trafficking, we generated receptor
mutants in which critical positions (Y383 and L386 or Y420 and
L423) were converted to alanines (Fig. 4A). The L424 residue
flanking the distal tyrosine-based motif was also mutated to
alanine to avoid the possibility of compensatory effects on 2
binding. In wild-type PAR1-expressing HeLa cells, 10 to 20%
of antibody-labeled cell surface receptor was constitutively
internalized at steady state (Fig. 4B and C). The PAR1
A383SIA386 mutant exhibited levels of constitutive and agonist-
FIG. 2. PAR1 constitutive internalization, but not agonist-induced internalization, is inhibited in AP2-depleted HeLa cells. (A) HeLa cells
stably expressing FLAG-tagged, wild-type PAR1 were transiently transfected with 50 nM siRNA targeted to either 2 or nonspecific (ns) mRNA
sequences. Surface FLAG-tagged PAR1 receptors were then labeled with the Ca2-dependent M1 anti-FLAG antibody for 1 h at 4°C. Cells were
then incubated (without agonist) for various times at 37°C to allow constitutive internalization of receptor-bound antibody. After incubations, cells
were stripped of antibody remaining bound to the cell surface with PBS–0.04% EDTA and lysed, and internalized antibody was then quantified
by enzyme-linked immunosorbent assay. Data (mean 	 standard error of the mean; n 
 3) are expressed as a percentage of initial cell surface
receptor-bound antibody, defined as total antibody bound to cells at 0 min and not washed with PBS-EDTA. Similar results were obtained in at
least three independent experiments. The immunoblot of equivalent amounts of cell lysates shown in the inset confirms the loss of 2 protein in
2 siRNA-transfected cells, whereas actin expression was unaffected. (B) PAR1-expressing HeLa cells transiently transfected with 2 or ns siRNAs
were labeled with antibody as described above and then incubated in the presence or absence of 50 M SFLLRN agonist peptide for 10 min at
37°C. Internalized receptor-bound antibody was quantified as described above. The data (mean 	 standard error of the mean; n 
 3) shown are
representative of at least three separate experiments. (C) PAR1-expressing HeLa cells transiently transfected with 2 or ns siRNAs were fixed,
permeabilized, and immunostained for 2-adaptin expression and imaged by confocal microscopy. The differential interference contrast (DIC)
image is the same field of 2-transfected cells shown in the adjacent anti-2-adaptin fluorescence image. (D) PAR1-expressing HeLa cells
transiently transfected with 2 or ns siRNAs were either left untreated (0 min) or treated in the absence or presence of 50 M SFLLRN for 10
min at 37°C. Cells were fixed, immunostained for PAR1, and imaged by confocal microscopy. The imaged cells are representative of many cells
examined in three different experiments. Insets are magnifications of boxed areas. Scale bar, 10 m.
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induced internalization similar to wild-type (Fig. 4B and C),
indicating that the proximal tyrosine-based motif is not essen-
tial for either process. In striking contrast, however, PAR1
A420KKA423A424 mutants failed to constitutively internalize,
suggesting that the distal tyrosine-based motif functions in
PAR1 tonic cycling (Fig. 4B and C). A similar defect in con-
stitutive internalization was observed upon mutation of only
the distal tyrosine (Y420) to alanine, whereas mutation of the
L423L424 residues had no significant effect (Fig. 4D), indicating
that the critical Y420 is essential for function. However, when
activated, the PAR1 A420KKA423A424 mutant internalized sim-
ilar to wild-type receptor (Fig. 4C), indicating that the distal
tyrosine-based motif is not essential for agonist-activated re-
ceptor internalization.
Immunofluorescence confocal microscopy was performed to
confirm the function of tyrosine-based motifs in receptor traf-
ficking. In untreated control cells, wild-type PAR1 and YXX Ø
mutants were each found predominantly at the cell surface and
did not colocalize with EEA1, a specific marker of early en-
dosomes (Fig. 5a to d). After 10 min at 37°C, wild-type PAR1
and A383SIA386 mutant moved from the cell surface to endo-
cytic vesicles and markedly colocalized with EEA1, suggesting
that constitutively internalized receptor transits through an
early endosomal compartment (Fig. 5a and b). Addition of
SFLLRN caused an even greater increase in wild-type PAR1
and A383SIA386 mutant internalization (Fig. 5a and b). In
contrast, A420KKA423A424 mutant PAR1 failed to redistribute to
EEA1-positive endosomes after 10 min at 37°C (Fig. 5c and d),
consistent with a lack of receptor constitutive internalization.
However, agonist treatment induced a significant amount of
A420KKA423A424 mutant internalization comparable to that of
wild-type receptor (Fig. 5c and d).
We next determined whether the distal tyrosine-based motif
(Y420KKL423) was important for PAR1 colocalization with en-
dogenous AP2 in cells. HeLa cells expressing wild-type PAR1
or A420KKA423A424 mutant were labeled with a polyclonal
anti-PAR1 antibody at 4°C so that only the surface receptor
cohort binds antibody. PAR1 recruitment to clathrin-coated
pits was then initiated by warming cells to 37°C for 2.5 min
(35). Cells were fixed and immunostained for PAR1 and
-adaptin, and colocalization was assessed by confocal mi-
croscopy. Approximately 29% of wild-type PAR1 localized to
distinct puncta that costained for the AP2 subunit -adaptin
(Fig. 6a). In contrast, A420KKA423A424 mutant remained pre-
dominantly in puncta that showed minimal colocalization with
-adaptin (Fig. 6b); only 8% of A420KKA423A424 mutant-
positive puncta costained for the -adaptin subunit. Thus, mu-
tation of the distal tyrosine-based motif disrupts PAR1 colo-
calization with endogenous AP2 in intact cells, consistent with
the failure of mutant receptor to undergo constitutive inter-
nalization.
These findings from cellular expression of PAR1 YXXØ mu-
tants suggest that the distal tyrosine-based motif Y420KKL423 is
critical to PAR1 constitutive internalization and colocalization
with AP2 in intact cells. We therefore tested whether this distal
motif was necessary for the observed direct binding of 2
protein to the PAR1 C-tail (Fig. 1A). Recombinant His6-
tagged 2 protein, purified from E. coli expression by nickel-
NTA and size exclusion chromatography (Fig. 7A), was in-
jected over streptavidin-coated SPR biosensors containing
immobilized biotinylated PAR1 C-tail peptides (Fig. 7B and
C). The dissociation constant (KD) for the binding of 2 to the
wild-type PAR1 C-tail was 7.5 	 1.3 M. In contrast, no
FIG. 3. AP2 is essential for endogenous PAR1 constitutive inter-
nalization, but not agonist-induced internalization, in HUVECs.
(A) HUVECs were electroporated with 2 or nonspecific (ns) siRNAs.
Cell lysates were prepared and immunoblotted (IB) for 2 expression
or actin expression. (B and C) HUVECs electroporated with 2 or ns
siRNAs were incubated with anti-PAR1 antibody for 1 h at 4°C; under
these conditions only receptors on the cell surface bound antibody.
Cells were washed and then incubated in the absence or presence of
100 M TFLLRNPNDK agonist peptide for 15 min at 37°C. Cells
were fixed, immunostained for PAR1 and 2-adaptin expression, and
imaged by confocal microscopy. These images are representative of
many cells examined in at least three independent experiments. The
insets are magnifications of boxed areas. Scale bar, 10 m.
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detectable binding was observed to the A420KKA423A424 mu-
tant PAR1 C-tail peptide at any concentration of 2 protein
tested (Fig. 7C), indicating that the distal YXXØ motif is
indeed required for direct 2 association.
Recovery of cellular thrombin signaling is dependent on
AP2-regulated PAR1 constitutive internalization. Constitutive
cycling of PAR1 between the plasma membrane and an intra-
cellular compartment results in a protected pool of uncleaved
receptors that repopulate the cell surface following thrombin
exposure without de novo receptor synthesis (13). This process
is critical for rapid cellular resensitization to thrombin signal-
ing. We therefore assessed the role of AP2 and tyrosine-based
motifs in the recovery of cellular thrombin responsiveness by
measuring thrombin-stimulated increases in intracellular Ca2
after an initial thrombin exposure in the presence of cyclohex-
imide, a protein synthesis inhibitor. Adding a saturating con-
centration of thrombin resulted in cleavage and activation of
all surface-bound wild-type or mutant PAR1 expressed in
HeLa cells (data not shown). In wild-type PAR1-expressing
cells, an initial exposure to thrombin induced a transient in-
crease in cytosolic Ca2 (Fig. 8A), comparable to that ob-
served in other cell types (13). Cells were immediately refrac-
tory to thrombin. After thrombin removal, cells were allowed
to recover for 20 min in the presence of hirudin (a thrombin
inhibitor) and cycloheximide and then exposed to thrombin
again, which elicited a second rise in intracellular Ca2 (Fig.
8A). This time course of recovery is similar to that observed
with PAR1-expressing fibroblasts (13). Cells expressing the
PAR1 A383SIA386 mutant also exhibited recovery of thrombin
signaling after an initial thrombin exposure (Fig. 8B). These
findings are consistent with the idea that wild-type PAR1 and
A383SIA386 mutant undergo constitutive internalization, gen-
erating an internal pool of protected receptors that recycles
back to the cell surface (13, 26). Cells expressing the PAR1
A420KKA423A424 mutant displayed an initial thrombin-stimu-
lated increase in cytosolic Ca2 comparable to wild-type receptor;
however, these cells failed to elicit a second response to thrombin
(Fig. 8C and D). The ability of PAR1 A420KKA423A424 mu-
tant-expressing cells to respond to carbachol, an agonist for
endogenous muscarinic acetylcholine receptors, indicates
that the cells were not globally defective in GPCR-stimu-
lated Ca2 mobilization after initial thrombin exposure
(Fig. 8E and F). Thus, the failure of PAR1 A420KKA423A424
mutant-expressing cells to regain thrombin signaling ap-
pears to be linked to the lack of an internal pool of un-
cleaved receptors that replenish the cell surface and permit
recovery of thrombin responsiveness.
We next examined whether AP2 regulation of PAR1 consti-
tutive internalization affected cellular resensitization to throm-
bin signaling. In PAR1-expressing HeLa cells transfected with
FIG. 4. A PAR1 cytoplasmic tail distal tyrosine-based motif regu-
lates constitutive but not agonist-induced receptor internalization.
(A) PAR1 cytoplasmic tail amino acid sequence is shown, and the posi-
tions of the tyrosine-based motifs are indicated. Superscripted numbers
indicate the critical tyrosines and leucines that were mutated to alanines.
The asterisk indicates the end of the protein sequence. (B) HeLa cells
stably expressing similar amounts of FLAG-tagged, wild-type PAR1 or
receptor mutants were labeled with antibody and incubated (without
agonist) for various times at 37°C, and internalized receptor was quan-
tified as described above. The data (mean 	 standard error of the
mean; n 
 3) shown are expressed as a percentage of total cell surface
receptor-bound antibody at 0 min and are representative of at least
three separate experiments. (C) HeLa cells stably expressing wild-type
PAR1 or receptor mutants were labeled with antibody and incubated
in the presence or absence of 50 M SFLLRN agonist peptide for 10
min at 37°C, and the amount of receptor internalization was quanti-
tated as described above. Data are representative of at least three
independent experiments. (D) HeLa cells expressing comparable
amounts of FLAG-tagged PAR1 wild-type, LL423/424AA, or
Y420A mutants were labeled with antibody, washed, incubated in
the presence or absence of 50 M SFLLRN agonist peptide for 30
min at 37°C, and then quantitated. The data (mean 	 standard error
of the mean; n 
 3) shown are representative of at least three
independent experiments. A significant difference in constitutive en-
docytosis of the Y420A mutant compared to wild-type receptor was
detected (, P  0.05), whereas no significant difference in constitutive
endocytosis of the LL423/424AA mutant compared to wild-type
receptor was detected. Statistical analysis was determined using an
unpaired Student’s t test. WT, wild-type; ASIA, A383SIA386; AKKAA,
A420KKA423A424.
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control siRNA, thrombin elicited an initial increase in cytosolic
Ca2, and after recovery virtually all cells regained thrombin
responsiveness (Fig. 9A and C). An initial Ca2 response to
thrombin was also observed in 90% of 2 siRNA-transfected
cells; however, after recovery only 20% of cells were capable
of eliciting a second response to thrombin (Fig. 9B and C). In
contrast, carbachol-induced calcium mobilization was main-
tained in the majority of 2 siRNA-transfected cells following
thrombin exposure (Fig. 9D), indicating that cells were capable
of responding to other GPCR agonists.
Resensitization of HUVECs to thrombin signaling was also
assessed. Nearly 80% of HUVECs electroporated with control
siRNA were initially responsive to thrombin and immedi-
ately refractory to a second thrombin exposure, but after a
20-min recovery period, almost all cells (75%) again elicited
a thrombin response (Fig. 9E and G). These findings are con-
sistent with the recovery of thrombin responsiveness previously
observed in these cells (13). In contrast, however, only 10%
of HUVECs with siRNA-mediated 2 knockdown regained
thrombin responsiveness following initial thrombin exposure
and a recovery period (Fig. 9F and G). Signaling by UTP, an
agonist for endogenous P2Y2 and/or P2Y4 GPCRs, was unper-
turbed, indicating that 2 siRNA-electroporated cells are re-
sponsive in general to GPCR activation after an initial throm-
bin exposure (Fig. 9H). Taken together, these findings strongly
suggest that AP2-dependent regulation of PAR1 constitutive
internalization is essential for recovery of cellular responses to
thrombin.
FIG. 5. Immunofluorescence reveals a critical role for the PAR1 cytoplasmic tail distal tyrosine-based motif in constitutive but not agonist-
induced internalization. HeLa cells expressing comparable amounts of wild-type (WT) PAR1 or receptor mutants were either left untreated (a to
d; 0 min) or incubated in the absence (a to d; 10 min) or presence (a to d; SFLLRN 10 min) of 50 M SFLLRN agonist peptide for 10 min
at 37°C. Cells were fixed and coimmunostained for PAR1 (green), using a polyclonal anti-PAR1 antibody, and for the early endosome marker
EEA1 (red), using a monoclonal anti-EEA1 antibody, and imaged by confocal microscopy. The insets are magnifications of boxed areas. The
imaged cells are representative of many cells examined in at least three independent experiments. Scale bar, 10 m. ASIA, A383SIA386; AKKAA,
A420KKA423A424.
FIG. 6. The distal tyrosine motif is important for PAR1 colocaliza-
tion with AP2 in intact cells. HeLa cells expressing PAR1 wild-type
(WT) or the distal tyrosine motif mutant A420KKA423A424 (AKKAA)
were prelabeled with anti-PAR1 antibody, washed, and then warmed
to 37°C for 2.5 min to initiate PAR1 recruitment to clathrin-coated
pits. Cells were fixed and coimmunostained for PAR1, (green) using a
polyclonal anti-PAR1 antibody, or for the AP2 subunit -adaptin
(red), using a monoclonal anti--adaptin antibody, and imaged by
confocal microscopy. Colocalization of PAR1 with AP2 is revealed by
the yellow areas in the merged image. The insets are magnifications of
boxed areas. The image shown is representative of many cells exam-
ined in three different experiments. Scale bar, 10 m.
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DISCUSSION
In the present study, we have defined a hitherto unknown
role for the clathrin adaptor AP2 in regulating PAR1 consti-
tutive internalization and restoring thrombin responsiveness to
endothelial cells and other cell types. The 2 subunit of AP2
directly interacts with a tyrosine-based motif present at the
extreme carboxy terminus of PAR1. This tyrosine-based motif
and AP2 function are each critical for maintaining an intracel-
lular store of protected receptors that replenish the cell surface
with uncleaved PAR1 after thrombin exposure, leading to re-
covery of thrombin signaling independent of de novo receptor
synthesis. Interestingly, internalization of agonist-activated PAR1
through clathrin-coated pits is independent of AP2, suggesting
that constitutive and agonist-induced receptor internalization
are specified by distinct molecular machinery. These findings
demonstrate a direct role for AP2 in regulation of PAR1 sig-
naling and trafficking.
Most GPCRs, including the well-characterized archetype of
the 2-adrenergic receptor, are rapidly phosphorylated following
activation, bind arrestins, and are then recruited to a clathrin-
and dynamin-dependent pathway for internalization from the
plasma membrane (33). Arrestins facilitate GPCR internaliza-
tion by binding directly to the clathrin heavy chain and the
2-adaptin subunit of AP2 (8, 10). We have shown in multiple
cell types that arrestins are not essential for PAR1 consti-
tutive or agonist-induced internalization (4, 25). In contrast,
we report here that the 2 subunit of AP2 directly binds to a
tyrosine-based motif in the cytoplasmic tail of PAR1 to medi-
ate constitutive internalization. Mutation of PAR1 distal ty-
rosine-based motif or depleting cells of AP2 by RNA interfer-
ence resulted in significant inhibition of receptor constitutive
internalization. Moreover, the PAR1 distal tyrosine-based mo-
tif was also important for receptor colocalization with endog-
enous AP2 in intact cells and critical for direct 2 binding in
vitro. The low-affinity binding of PAR1 with the 2 subunit of
AP2 as observed in our studies (KD, 7.5 M) is typical of the
moderate to weak interaction of 2 with proteins bearing ty-
rosine-based motifs previously reported (22, 31) and may have
precluded our ability to detect PAR1 interaction with AP2
using cell lysate-based approaches of coimmunoprecipitation
or pull-downs. Such low-affinity protein-protein interactions
are biologically relevant and, in fact, are required to allow for
the dynamic assembly and disassembly of the protein network
that drives clathrin-coated vesicle budding at the plasma mem-
brane (23). A high-affinity interaction between PAR1 and 2
would be detrimental, resulting in significant internalization of
the receptor at steady state and rendering it unavailable to its
extracellular stimuli.
In addition to PAR1, we found that several other human
GPCRs contain sequences conforming to the canonical YXXØ
motif within their cytoplasmic tails (see Fig. S4 in the supple-
mental material), suggesting that AP2 might function in traf-
ficking of other GPCRs. Indeed, the 2 subunit of AP2 was
previously shown to directly interact with the C tail of the
1b-adrenergic receptor (7). However, in this case, 2 binds to
an unusual stretch of eight arginine residues (rather than a
canonical YXXØ motif) within the C-tail of the 1b-adrenergic
receptor. This study also reported that an lb-adrenergic re-
ceptor mutant, in which the arginine stretch was deleted, failed
to bind 2 in vitro, and displayed defects in agonist-induced
endocytosis, suggesting that this region (and perhaps AP2
binding) is important for activated lb-adrenergic receptor in-
ternalization. The constitutively active human viral chemo-
kine US28 GPCR has also been reported to internalize
through a clathrin-dependent pathway involving AP2 and
not arrestins (9). However, whether AP2 directly binds to a
FIG. 7. The distal tyrosine-based motif is necessary for direct as-
sociation between the PAR1 cytoplasmic tail and purified recombinant
2 protein. (A) His6-tagged 2 protein was expressed in E. coli by
IPTG induction, and soluble, monodispersed protein was purified by
sequential application of Ni-NTA resin and size exclusion chromatog-
raphy. (B) Representative binding curves were generated by injecting
15 M purified His6-tagged 2 protein over immobilized PAR1 C-tail
peptide surfaces, followed by subtracting corresponding traces from a
blank negative control surface. (C) Increasing concentrations of His6-
tagged 2 protein (0.01 to 50 M) were injected separately over
peptide biosensor surfaces, and binding curves were generated as de-
scribed in panel B. The resulting maximal resonance units obtained
during the analyte association phase were then plotted versus analyte
concentration to generate a one-site binding curve, indicating a disso-
ciation constant (KD) of 7.5 	 1.3 M for wild-type PAR1 C tail. No
detectable binding was observed for the PAR1 A420KKA423A424
(AKKAA) mutant peptide surface, even at the saturating concen-
tration of 50 M.
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YXXØ motif present in the C-tail region of US28 receptor
remains to be determined. Together, these findings suggest
that the clathrin adaptor AP2 functions in distinct modes of
GPCR trafficking, including constitutive internalization of
unactivated PAR1, activated 1b-adrenergic receptor inter-
nalization, and uptake of the constitutively active viral che-
mokine US28 receptor.
Our study also indicates that the trafficking behaviors of
unactivated versus activated PAR1 are regulated by distinct
endocytic machinery. PAR1 constitutive internalization was vir-
tually abolished in cells depleted of AP2, whereas agonist-acti-
vated receptor internalization remained intact (Fig. 2 and 3).
Activated PAR1 internalized via a clathrin- and dynamin-
dependent pathway in AP2 depleted cells, excluding the pos-
sibility that the receptor uses an alternate non-clathrin endo-
cytic route (see Fig. S3 in the supplemental material). Our
previous studies suggest that internalization of agonist-acti-
vated PAR1 is critically dependent on phosphorylation of the
C-tail region (25, 32). Activated PAR1 phosphorylation might
induce a conformational change within the C-tail region to
expose an endocytic-sorting motif and/or to promote binding
of clathrin adaptor proteins. We previously showed that mu-
tation of the proximal tyrosine-based motif partially inhibits
the endocytosis of activated PAR1 that is only evident after
prolonged agonist exposure (26). However, AP2 does not ap-
pear to be involved in this process since, in the current studies,
we find that AP2 is not essential for activated PAR1 internal-
ization (Fig. 2 and 3). Thus, whether other clathrin adaptor
proteins such as epsin or CALM bind directly to this motif or
elsewhere to PAR1 intracytosolic domains to regulate AP2-
independent internalization of activated PAR1 through clath-
rin-coated pits is not known. Internalization of activated PAR1
may be additionally dependent on ubiquitination or deubiq-
uitination processes. The transient modification of GPCRs
and/or associated proteins by ubiquitination is known to facil-
itate trafficking through the endocytic pathway (14).
FIG. 8. PAR1 mutants defective in constitutive internalization fail to regain thrombin responsiveness. HeLa cells stably expressing similar
amounts of wild-type (WT) PAR1 or receptor mutants grown on coverslips were pretreated with 10 M cycloheximide for 90 min to block de novo
protein synthesis, loaded with Fura2-AM, and then stimulated with thrombin (-Th) as indicated. The Ca2 responses (i.e., [Ca2]i, intracellular
Ca2 concentration) were quantified as described in Materials and Methods. Cells were first exposed to 30 nM thrombin for 10 min at 37°C, and
the traces shown represent Ca2 responses of at least 10 cells from a single field, all of which responded to thrombin. The presence of agonists
and time of exposure are indicated by the bars below and above the traces. Between stimulations, cells were washed with medium containing the
thrombin inhibitor hirudin (0.5 U/ml) and allowed to recover for 20 min at 37°C. (A and B) Wild-type (WT) PAR1 and PAR1 A383SIA386
mutant-expressing cells responded to a second 10 nM thrombin stimulus as well as to 2 M A23187, a calcium ionophore. Similar results were
observed in three independent experiments. (C to F) HeLa cells expressing the PAR1 A420KKA423A424 mutant failed to elicit a second response
to 10 nM thrombin but retained the capacity to respond to 500 M carbachol (CARB), an agonist for endogenous muscarinic acetylcholine
GPCRs, or to the calcium ionophore A23187 (2 M). Similar findings were observed in three separate experiments. ASIA, A383SIA386; AKKAA,
A420KKA423A424.
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The proteolytic activation of PAR1 is unique among
GPCRs, and distinct intracellular pathways have evolved to
dispose of irreversibly activated receptors and to replenish the
cell surface with uncleaved receptors after thrombin exposure.
Our findings strongly suggest that AP2-dependent constitutive
internalization of PAR1 is critical for resensitizing cells to
thrombin signaling. In human platelets, which presumably re-
spond to thrombin only once, the majority of PAR1 is retained
FIG. 9. AP2 is essential for restoring thrombin signaling in HUVECs and other cell types. PAR1-expressing HeLa cells were transiently transfected
with 50 nM 2 or NS siRNA, and HUVECs were electroporated with 600 nM 2 or nonspecific (ns) siRNAs as described in Materials and Methods.
Cells were grown on coverslips, pretreated with 10 M cycloheximide, loaded with Fura2-AM, and then exposed to thrombin (-Th) as indicated. The
intracellular Ca2 response traces from individual cells are shown in various panels, whereas the responses from an average of 20 to 30 cells imaged from
three separate experiments are shown as bar graphs in panels C, D, G, and H. Cells were first exposed to 30 nM thrombin for 10 min at 37°C, and 80%
of these cells responded to thrombin. Cells were washed with medium containing hirudin (0.5 U/ml) and then exposed to 10 nM thrombin again. In
control ns siRNA-treated cells, thrombin elicited a second Ca2 response in virtually the same percentage of cells that were initially responsive to
thrombin. In 2 siRNA-treated cells, only 1 to 2 cells out of 20 cells were responsive to thrombin after an initial thrombin exposure (panels C and G).
The difference between the number of cells eliciting -thrombin-induced calcium response in 2 siRNA-treated cells compared to ns siRNA control-
treated cells was significant (, P  0.01; , P  0.05) as determined using an unpaired Student’s t test. HeLa cells and HUVECs retained the capacity
to respond to 500 M carbachol (CARB) or 100 M UTP, agonists for endogenously expressed muscarinic and purinergic GPCRs, respectively (panels
D and H), and to the calcium ionophore A23187 (2 M). Similar results were observed in at least three independent experiments.
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on the cell surface and fails to internalize (19). Thus, platelets
lack an internal pool of protected receptors as recovery of
thrombin responsiveness is not a physiological requirement for
this cell type. In contrast, endothelial cells and fibroblasts are
exposed to thrombin repeatedly and need to recover thrombin
signaling in a timely manner. This appears to be accomplished
by the movement of uncleaved PAR1 from an intracellular
compartment to the cell surface to permit rapid recovery of
thrombin signaling independent of de novo receptor synthesis
(13). Evidence presented here supports this model. In cells
expressing PAR1 tyrosine mutants or in cells depleted of AP2
by RNA interference, uncleaved receptor fails to constitutively
internalize and accumulate in an intracellular store. Conse-
quently, PAR1 is not protected from thrombin cleavage and
cells are unable to regain thrombin responsiveness. However,
cells retained the capacity to elicit calcium responses to other
endogenous GPCR agonists, indicating that receptor activa-
tion is not globally disrupted. Several other GPCRs including
PAR2 and the thromboxane A2 receptor  isoform have also
been reported to constitutively internalize, resulting in an in-
tracellular store of unactivated receptors (2, 28). A noncanoni-
cal YX3Ø motif is present in the cytoplasmic tail of thrombox-
ane A2 receptor (29), whereas PAR2 lacks such tyrosine-based
sequences. The mechanism mediating constitutive internaliza-
tion of these receptors as well as its physiological relevance
remains poorly defined.
Our studies provide the first insight into the molecular
mechanisms responsible for PAR1 constitutive internalization
and cellular resensitization to thrombin signaling. The proteo-
lytic nature of PAR1 activation is distinct from most reversibly
activated GPCRs. Consequently, endothelial cells and other
cell types, which need to respond to thrombin repeatedly over
time, have evolved specialized mechanisms to permit rapid
recovery or maintenance of thrombin responsiveness. Throm-
bin and PAR1 are important mediators of endothelial cell
activation and migration during vascular development and in
response to vascular injury (11, 42). Cell migration requires
repeated sampling of the local environment in order to detect
changes in agonist concentrations and gradients. It will be
important to determine whether disruption of PAR1 tonic
cycling and failure of endothelial cells to rapidly recover
thrombin signaling are critical for endothelial cell activation
and/or migration in vivo.
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